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Turner Syndrome (TS) is an unfavorable genetic condition with a prevalence of 1:2500 in newborn girls.
Prompt and effective diagnosis is very important to appropriately monitor the comorbidities. The aim of the
present study was to propose a feasible and practical molecular diagnostic tool for newborn screening by
quantifying the gene dosage of the SHOX, VAMP7, XIST, UBA1, and SRY genes by quantitative polymerase
chain reaction (qPCR) in individuals with a diagnosis of complete X monosomy, as well as those with TS
variants, and then compare the results to controls without chromosomal abnormalities. According to our results,
the most useful markers for these chromosomal variants were the genes found in the pseudoautosomic regions 1
and 2 (PAR1 and PAR2), because differences in gene dosage (relative quantification) between groups were
more evident in SHOX and VAMP7 gene expression. Therefore, we conclude that these markers are useful for
early detection in aneuploidies involving sex chromosomes.
Introduction
Turner syndrome (TS) affects 1 in 2500/3000 live-born girls and is characterized by short stature, gonadal
dysgenesis, pterygium colli, cubitus valgus, and a low hair-
line (Wiedemann and Glatzl, 1991; Ranke and Saenger,
2001; Pinsker, 2012). It is caused by partial or total loss
of the second sex chromosome (Ford et al., 1959; Sybert and
McCauley, 2004). Complete monosomy X (45,X) repre-
sents 50–60% of all cases, while mosaics of two or more
cell lines and structural aberrations (mostly Xq isochromo-
somes) account for the remaining 40–50% (Sybert and
McCauley, 2004).
The X chromosome has 155 megabase pairs (Mb) and
contains *1000 genes (Bianchi et al., 2012), while the Y
chromosome (60Mb) contains only 104 protein-coding se-
quences out of a total of over 200 genes (Li et al., 2008).
Inactivation of the majority of one X chromosome in females
leads to a functional 1n dosage of X-linked genes in both
genders. The pseudoautosomal regions (PAR)1 and 2 ho-
mologous sequences, which are present on both the X and Y
chromosomes, escape from X chromosome inactivation.
Therefore, the 24 genes present in the 2.6Mb PAR1 (Mangs
and Morris, 2007) and the 4 genes in the 320 kb PAR2 have a
functional gene dosage of 2n in both genders. Hence, the
etiology of TS lies in the haploinsufficiency of genes located
in the PAR1 (Zhong and Layman, 2012).
Guidelines of the American College of Endocrinology for
the management of patients with TS emphasize the benefit of
early detection through newborn screening methods (Bondy
et al., 2007). However, only 20–30% of TS patients are di-
agnosed during the first year of life and another 25% are
diagnosed in adulthood (Massa et al., 2005; Stochholm et al.,
2006). InMexico, less than 15% are diagnosed during the first
year of life. Early detection allows identification of mal-
formations of the cardiovascular system and prevention or
management of short stature, hearing problems, and learning
difficulties (Bondy et al., 2007; Pinsker, 2012). Moreover, it
is feasible to diminish the risk of infertility in some indi-
viduals by cryopreserving oocytes while follicles are still
viable (Kavoussi et al., 2008; Borgstrom et al., 2009).
The dosage reduction of genes located in PARs1 and 2,
which is inherent to the complete or partial loss of the second
sex chromosome, can be sensitively quantified by quantita-
tive polymerase chain reaction (qPCR), as reported for the
ARSE gene in Xp22.33 (Rocha et al., 2010).
The aim of the present study was to determine the dosage
of two genes located in the pseudoautosomal regions (short-
stature homeobox [SHOX] and vesicle-associated membrane
protein 7 [VAMP7]), two X-specific genes (ubiquitin-like
modifier activating enzyme 1 [UBA1] in p, and X inactive-
specific transcript [XIST] in q), the sex determining region Y
(SRY) gene by qPCR in TS patients, and to compare the
results to those for the gene dosage of men and women with a
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normal karyotype. These findings were used to evaluate the
effectiveness of these measurements as an affordable method
for TS screening.
Materials and Methods
Population
We performed a descriptive, comparative, nonblinded
study that included 27 TS patients who were karyotyped
between 2005 and 2012 by the Genetics Department, Uni-
versity Hospital, ‘‘Dr. Jose E Gonza´lez’’ of the Universidad
Auto´noma of Nuevo Leo´n in Monterrey, Me´xico. Volunteer
subjects with a normal karyotype (10 females and 10 males)
were recruited from the same institution and used as controls.
Written informed consent was obtained from all subjects or
legal guardians, and the Health Research Ethics Board of the
UANL Medical School approved the study (Approval No.:
GN-11-004).
The subjects were divided into four groups according to
their karyotype: (a) 45,X (X monosomy); (b) 46,XY (male);
(c) 46,XX (female); and (d) TS variants (mosaicism and
structural aberrations).
Sample collection
Biological blood samples. Four milliliters of peripheral
venous blood was collected in a heparin-treated tube from
Table 1. Relative Quantification Results for the SHOX, XIST, VAMP7, SRY, UBA1 Genes
Case Karyotype RQ SHOX RQ XIST RQ VAMP7 RQ SRY RQ UBA1
1 45,X 0.531 0.474 0.537 0 0.559
2 45,X 0.571 0.501 0.491 0 0.502
3 45,X 0.532 0.561 0.609 0 0.462
4 45,X 0.572 0.38 0.47 0 0.649
5 45,X 0.505 0.462 0.451 0 0.521
6 45,X 0.556 0.513 0.609 0 0.564
7 45,X 0.494 0.549 0.531 0 0.519
8 45,X 0.545 0.512 0.534 0 0.508
9 45,X 0.479 0.51 0.525 0 0.513
10 45,X 0.624 0.638 0.637 0 0.46
11 45,X 0.472 0.516 0.645 0 0.53
12 45,X 0.518 0.421 0.492 0 0.722
13 45,X,inv (7)(q31.2-pter) 0.509 0.515 0.479 0 0.537
14 45,X[6]/46,XX[24] 1.169 0.733 0.479 0 0.824
15 45,X[2]/46,XX[28] 0.8 0.871 0.777 0 1.602
16 45,X[18]/46,XX[12] 0.623 0.605 0.629 0 0.611
17 45,X[12]/46,XX[18] 0.535 0.718 0.761 0 0.533
18 45,X[13]/46,XX[7] 0.59 0.689 0.711 0 0.702
19 45,X[6]/47,XXX[24] 1.016 1.108 1.084 0 1.079
20 45,X[10]/49,XXXX[3]/46,XX[86] 0.99 0.906 0.899 0 1.034
21 45,X[6]/47,XXX[24] 0.703 0.63 0.616 0 0.762
22 45,X[20]/46,XY[10] 0.809 0.509 0.792 0.561 0.542
23 45,X[17]/46,XY[3] 0.859 0.484 0.458 1.784 0.549
24 45,X[17]/46,X,r[13] 0.506 0.688 0.473 0 0.694
25 45,X[5]/46,X,i(X)(q10)[25] 0.53 1.053 1.146 0 0.514
26 45,X[6]/46,X,i(X)(q10)[24] 0.527 1.012 1.097 0 0.558
27 46,X,i(X)(q10) 0.5 1.026 1.535 0 0.973
28 46,XX 1 1.062 1.083 0 1.012
29 46,XX 1 1 1 0 1
30 46,XX 1 1 1 0 1
31 46,XX 1 1 1 0 1
32 46,XX 1 1 1 0 1
33 46,XX 0.908 1.111 1.039 0 0.999
34 46,XX 1 1 1 0 1
35 46,XX 1 1 1 0 1
36 46,XX 1 1 1 0 1
37 46,XX 1 1 1 0 1
38 46,XY 1.069 0.513 1.127 0 0.536
39 46,XY 0.952 0.56 1.105 2.737 0.533
40 46,XY 1.025 0.561 1.103 0 0.548
41 46,XY 1.052 0.558 1.613 0 0.495
42 46,XY 0.994 0.491 0.971 0 0.507
43 46,XY 0.959 0.506 1.097 3.897 0.511
44 46,XY 1.005 0.487 1.104 0 0.524
45 46,XY 0.981 0.472 1.016 0 0.552
46 46,XY 1.053 0.488 0.999 0 0.547
47 46,XY 1.169 0.512 1.164 1.007 1.042
RQ, relative quantification.
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each participant for G-banding karyotype (Barch et al.,
1997) in our laboratory, which is accredited by the College
of American Pathologists (CAP). Only four patients and
the control subjects were karyotyped during this study.
Twenty-three patients who had been previously kar-
yotyped and diagnosed with TS were invited to participate,
and a 4-mL blood sample was collected in EDTA tubes to
obtain total genomic DNA. Extraction was conducted us-
ing an automated QIAcube instrument and QIAamp
DNA Mini and Blood Mini Extraction Kits (Qiagen,
Valencia, CA).
Gene selection. Five probe-on-demand assays (Applied
Biosystems, Foster City, CA) were used to measure the
dosage of five genes: SHOX at PAR1, VAMP7 at PAR2,
UBA1 at Xp11.23, XIST at Xq13.2, and SRY at Yp11.3 (Table
1). The RNase P gene was used as an autosomal reference
control.
Real-time PCR analysis. The dosage of each gene was
measured with the StepOnePlus System (Applied Biosys-
tems) and TaqMan Genotyping Master Mix 2X (Applied
Biosystems) following the manufacturer’s instructions. Re-
lative quantification (RQ) values were obtained using the
Delta CT comparison method (DDCT) (Livak and Schmitt-
gen, 2001). Amplification reactions were performed in trip-
licate with determined reproducibility. In TS patients, an RQ
< 1 for SHOX and VAMP7 was expected.
Statistical analysis
Descriptive statistics were applied to the RQ values of each
gene. ANOVA was used to analyze intergroup differences
between gene dosages, which were determined by the mean
RQ values of each gene. Differences were considered sta-
tistically significant when the p-value was < 0.05.
Results
Of the 47 samples, 20 were from the control group (10
46,XY and 10 46,XX) and 27 from TS patients. Among the
latter, 13 (48%) had monosomy X and 14 had a TS variant,
with 45,X/46,XX mosaicism being the most frequent (19%)
karyotype (Table 1).
The RQ value of the SHOX gene in patients with TS ranged
from 0.50 (minimum) to 0.85 (maximum) and it ranged from
0.97 to 1.07 in the control group (Table 1). The VAMP7 gene
presented an RQ range from 0.47 to 0.57 in patients diag-
nosed with complete X monosomy (Table 1) and from 0.57 to
0.99 for the TS chromosomal variants. The RQvalues from the
control group ranged from 0.99 to 1.25. The RQ values for the
XIST gene in the patients with complete X monosomy ranged
from 0.46 to 0.54 and from 0.66 to 0.90 in the TS variant
group. In contrast to the patients, the RQ for the control group
ranged from 0.98 to 1.04 in female subjects with a 46,XX
karyotype and from 0.49 to 0.53 in males with a 46,XY kar-
yotype (Table 1). In the case of the UBA1 gene, the RQ in
patients with complete X monosomy was from 0.49 to 0.58,
FIG. 1. Box and whisker plot of relative quantification (RQ) results from the four groups evaluated.
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and in the TS variant group, the RQ values ranged from 0.60 to
0.95. The control group RQ range for the same gene was from
0.99 to 1.00 for 46,XX and from 0.46 to 0.69 for 46,XY. The
SRY gene RQ in patients with complete X monosomy was 0.0,
ranging from 0.47 to 0.66 in the TS variant group. For the
controls, the RQ for the SRY gene was 0.0 in the 46,XX female
subjects and from 0.97 to 1.09 in male 46,XY subjects.
The ANOVA showed significant differences ( p< 0.05) in
the gene dosage for SHOX, XIST,UBA1, and VAMP7 between
the study groups and the controls. The most useful markers for
the TS variant group (mosaicism and structural aberration)
were those found in PAR1 and PAR2 and SHOX and VAMP7,
which showed more consistent results and a greater ability to
discern between the TS patients versus controls (Fig. 1).
In the descriptive analysis, the RQ ranges of SHOX and
VAMP7 obtained from the TS groups showed a difference of
more than– 3 standard deviation from that of the control
group. The RQ cutoff was established at 0.8, with a sensitivity
and a specificity of 100% in patients with completemonosomy
X and a sensitivity of 64% and a specificity of 100% for the TS
variants. If we analyzed mosaic TS (45,X/46,XX) only, the
sensitivity lowers to 83% and to 64% in TS variants.
All of the gene markers in patients with different chro-
mosomal variants were evaluated to analyze whether the
chromosomal formula could be identified without a con-
ventional karyotype. Using individuals with a 46,XX kar-
yotype as a reference, a difference between the gene dose of
XIST and UBA1 was found; however, when compared to
46,XY individuals, who are hemizygous for these genes, the
RQ was similar to that found in most patients with TS. Thus,
the RQ for XIST and UBA1 was not considered to be useful
for analysis and diagnosis (Fig. 1). The SRY gene is only of
qualitative utility because it identifies individuals with a
46,XY chromosomal formula.
Discussion
Early diagnosis of TS leads to proper treatment of compli-
cations and can aid in avoiding or reducing deleterious con-
sequences in adult life. The frequent delay in the diagnosis
of TS justifies the search for methodologies that allow prompt
diagnosis of partial or complete, homogeneous or mosaic, and
X chromosome monosomy. In the present study, we analyzed
27 patients with TS to determine the gene dosage of SHOX,
VAMP7, XIST, UBA1, SRY, and RNase P in 47 individuals.
The groupwith completemonosomyX represented 48%of all
samples in the study group. Of the remaining TS patients, 19%
weremosaic with 45,X/46,XX, followed by othermosaics and
structural aberrations present in similar proportions to those
reported in the literature (Sybert and McCauley, 2004).
In our study, the differences between RQ means in the
patients with complete monosomy and control subjects were
significantly different. Similar findings have been reported by
Rocha et al. (2010).
Overall, the patients had half of the dosage (compared to
46,XX women) in all X chromosome genes analyzed and the
absence of the SRY gene. If the analysis of the studied genes is
used as a screening test in a population, it will differentiate
between individuals with a 46,XY karyotype and TS patients.
Detection of the SRY gene is considered of great importance
in patients with mosaic forms of TS (Coto et al., 1995;
Mendes et al., 1999; Gravholt et al., 2000). The analysis of
the RQ for the SRY gene in the present study will permit
the detection of variants of TS with the presence of a Y
chromosome (this occurs in 3–5% of TS cases), which in-
creases the risk for gonadal tumors, especially gonado-
blastoma (Osipova et al., 1998). Therefore, we believe that
including this gene (SRY) in our analysis provides a more
useful tool for the study of patients with TS.
Patients with mosaic 45,X/46,XY had a decreased RQ for
SHOX and VAMP7 compared to normal males (46,XY).
Differences in the mean RQ values observed in samples
with chromosomal variants were not as clear-cut, especially
in the case of mosaics with a 45,X clone present below 20%
(cases 14 and 20) and in mosaics with polysomy X (e.g., case
19) that presented an RQ ‡ 1. We think that the extra X
chromosome compensates for the monosomyX in other cells.
As expected, the most evident gene dosage alterations were
observed in SHOX and VAMP7, which thereby appear to be
reliable and useful markers in diagnosing TS (Fig. 1). De-
tection sensitivity for the different TS variants altogether was
64%, but when only mosaic forms were analyzed (45,X/
46,XX), sensitivity increased up to 83%. It is important to
mention that this genotype is the second most common after
monosomy (Sybert and McCauley, 2004; Davenport, 2010).
Despite the low number of participants—a limitation of our
study that should be addressed to increase the statistical
power—the use of qPCR to determine the dosage of SHOX and
VAMP7 appears to be a useful, quick, and affordable neonatal
screening test in infants with clinical suspicion of TS.
The delay in TS diagnosis is a problem, and methodologies
that allow early diagnosis of patients, including those with
chromosomal variants, are needed. Guidelines of the Amer-
ican College of Endocrinology for the management of pa-
tients with TS have addressed the potential benefit of
designing a newborn screening method for the detection of
these patients (Bondy et al., 2007). We propose the quanti-
fication of the gene dose of SHOX and VAMP7 as a screening
tool for the diagnosis of newborns with TS.
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